• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
      • shARC Platform
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Celyad’s R&D day 2019

August 12, 2019 By Celyad

Members of the Celyad leadership team will provide an overview of the recent breakthroughs in the R&D pipeline, updates on key clinical trials and the Company’s cell therapy manufacturing capabilities. In addition, Celyad will unveil its next-generation NKG2D preclinical program CYAD-02 as well as the Company’s proprietary non-gene edited allogeneic platforms including the CYAD-200 series of shRNA-based CAR-T programs.

Footer

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use